| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 32.936 | 49.083 | 50.313 | 54.992 | 44.217 | 50.673 | 56.807 | 52.636 | 50.489 | 50.361 |
| Total Income - EUR | 31.070 | 49.601 | 50.256 | 57.117 | 44.281 | 51.577 | 58.794 | 50.796 | 51.021 | 51.928 |
| Total Expenses - EUR | 23.335 | 37.102 | 45.867 | 57.436 | 40.268 | 44.320 | 51.104 | 42.674 | 45.670 | 47.326 |
| Gross Profit/Loss - EUR | 7.736 | 12.499 | 4.389 | -319 | 4.013 | 7.257 | 7.690 | 8.122 | 5.350 | 4.601 |
| Net Profit/Loss - EUR | 6.734 | 10.844 | 2.571 | -931 | 3.553 | 6.783 | 7.219 | 7.709 | 4.895 | 4.382 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Noblesse Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.115 | 1.334 | 28.301 | 26.477 | 53.510 | 50.420 | 44.803 | 38.205 | 31.738 | 22.618 |
| Current Assets | 21.910 | 27.503 | 30.432 | 34.759 | 22.094 | 24.915 | 24.060 | 30.753 | 38.462 | 49.843 |
| Inventories | 10.068 | 8.997 | 8.819 | 7.466 | 7.564 | 9.605 | 11.869 | 10.974 | 10.349 | 20.858 |
| Receivables | 11.638 | 13.628 | 20.977 | 23.466 | 5.416 | 3.508 | 1.723 | 1.320 | 2.172 | 1.961 |
| Cash | 204 | 4.878 | 635 | 3.827 | 9.114 | 11.801 | 10.468 | 18.458 | 25.941 | 27.024 |
| Shareholders Funds | 8.524 | 19.282 | 21.526 | 20.200 | 53.635 | 64.265 | 64.602 | 67.165 | 68.934 | 71.292 |
| Social Capital | 12.886 | 12.755 | 12.539 | 12.309 | 12.071 | 11.842 | 11.579 | 11.615 | 11.580 | 11.515 |
| Debts | 15.640 | 9.827 | 37.467 | 41.170 | 22.148 | 11.214 | 4.790 | 2.833 | 2.125 | 1.553 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Noblesse Pharma Srl